Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004.
about
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in womenDrug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 updateSurveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, ZimbabweLow primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, RwandaModerate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National SurveyPersistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort studyResistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia.Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.Primary drug resistance in South Africa: data from 10 years of surveys.Drug resistance surveillance in resource-poor settings: current methods and considerations for TB, HIV, and malaria.Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa.Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia.Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South AfricaPrevalence of antiretroviral drug resistance mutations and HIV-I subtypes among newly-diagnosed drug-naïve persons visiting a voluntary testing and counselling centre in northeastern South Africa.Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programmeThe global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention.Surveillance of transmitted drug-resistant HIV among young pregnant women in Ouagadougou, Burkina Faso.Prevalence of transmitted HIV drug resistance among newly diagnosed antiretroviral therapy-naive pregnant women in Lilongwe and Blantyre, Malawi.A retrospective survey of HIV drug resistance among patients 1 year after initiation of antiretroviral therapy at 4 clinics in MalawiDrug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis.Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapineThe use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy.Pre-treatment drug resistance among patients initiating antiretroviral therapy (ART) in Zimbabwe: 2008-2010.Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical TrialLow prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya.The prevalence of transmitted drug resistance in newly diagnosed HIV-infected individuals in Croatia: the role of transmission clusters of men who have sex with men carrying the T215S surveillance drug resistance mutation.Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009.Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR.Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: evidence for low level of transmitted drug resistance.Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South AfricaViral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switchSwitching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.Tuberculous meningitis is associated with higher cerebrospinal HIV-1 viral loads compared to other HIV-1-associated meningitides.HIV-Positive Kidney Donor Selection for HIV-Positive Transplant Recipients.
P2860
Q24629582-85F4167D-A280-4158-9CAD-34EBAD53FA0EQ28474918-23F0C4C9-8A2B-47AA-8AA5-9DA590256DC1Q28478615-E6618AB1-5736-4981-81AF-D2FC49403018Q28535266-1331162B-EE04-40F9-A8AB-5E4CA2ACBA1DQ28554729-040B941B-011A-417D-9B05-EEE9298F3725Q33605273-E6E426E0-7326-45B5-8706-33E58414F377Q33637867-B64D26B2-C6E3-4647-88EC-D39841A0B342Q33714130-8A905740-5848-47B1-8CEF-40A54879164EQ33820125-08297A15-D652-478A-9323-1D2350949341Q33952538-8E8B81BD-D083-43E1-8269-615DC37AFAB7Q34112568-C551AAF8-3097-4868-A5A1-1B0CA34FE1D0Q34129300-557E7021-80ED-41F1-8620-D8C1A188E29DQ34531112-86395E8A-AFEC-4B9C-A842-BAAC199F2435Q34606742-5595089A-B12D-4BC9-BAD7-83F5DCEBE6F7Q35102225-88496360-D70F-48FF-95C0-D554AC9EFD37Q35179391-E3DCC386-36EA-4FDA-A778-43152471D32CQ35217629-3232AD4A-F306-4192-9D3C-0F9F0B6C3025Q35305667-2C073168-9945-45E9-A26B-86AF97B4A8FDQ35403205-6D1CF0B9-7031-416E-A054-16F9F154644EQ35536296-6C9349DC-4D18-4E71-807C-A7F84831E37EQ35809718-2D231C1A-DC25-4329-A3EE-C9889665BE1DQ35917550-16F2B0B7-3978-4618-81BE-DA6F069AD0ECQ35917559-9A3ECDC9-E15D-4264-8E33-1BA596FE7C5EQ35917568-23588AED-0525-4F0A-AA9E-9B860C8EE6ECQ35965344-D05B917D-757F-4487-9060-5AEDD704C412Q35965722-9B85E37A-5EFA-4C87-9181-2C3753C11E6FQ35990257-E53EC090-55EA-4BCF-B002-DE70B6F80428Q36032235-DF761A65-77A2-4D95-B7F2-8F8B077285C9Q36049082-319E77CE-A9B0-4230-BC2B-DC051CC8D63FQ36306986-E7D4C891-40D0-40FC-933D-C2F5BEC47D28Q36509589-49BA09A7-476B-4245-AE49-FE77CBD5698AQ36553994-9D78FFE6-CB7A-4019-BEDA-38A2C27BD68DQ36611216-E6CFE11C-3358-4136-B90A-95F2A909D176Q37247625-87EF2565-5BC3-4D03-9E1F-6920D7ED030CQ37247746-9D26E8C6-F9D0-4137-AD18-647768B0B5B6Q37461877-2B7C1CD0-25C1-4D5B-9250-FD924DFF540CQ37582314-39522C25-8C25-4AC1-8F6D-3F3FCE4411DAQ40238381-3D734DF5-3C35-491C-807D-0904EB291842Q47546881-4A00E625-5732-4DB5-ADFC-D74B5F4DF1E0Q47554143-98F0DEF7-1861-4B51-A34E-1C9CFDDCFF39
P2860
Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Antiretroviral drug resistance ...... South Africa in 2002 and 2004.
@en
Antiretroviral drug resistance ...... South Africa in 2002 and 2004.
@nl
type
label
Antiretroviral drug resistance ...... South Africa in 2002 and 2004.
@en
Antiretroviral drug resistance ...... South Africa in 2002 and 2004.
@nl
prefLabel
Antiretroviral drug resistance ...... South Africa in 2002 and 2004.
@en
Antiretroviral drug resistance ...... South Africa in 2002 and 2004.
@nl
P2093
P1433
P1476
Antiretroviral drug resistance ...... South Africa in 2002 and 2004
@en
P2093
Adrian Puren
Beverly Singh
Diane E Bennett
Gillian Hunt
Johanna Ledwaba
Lindiwe Makubalo
Mpho Rakgotho
Visva Pillay
P304
P478
13 Suppl 2
P50
P577
2008-01-01T00:00:00Z